

4 November 2024

RESULTS OF ANNUAL GENERAL MEETING

Botanix Pharmaceuticals Ltd (ASX:BOT) ("Botanix" or the "Company") wishes to advise pursuant to Listing Rule 3.13.2 that all resolutions presented at the 2024 Annual General Meeting of Shareholders held today were carried by a poll.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises details of the resolutions and the votes received in respect of each resolution are set out in the attached summary.

Release authorised by the Board of Directors.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital

Disclosure of Proxy Votes

Botanix Pharmaceuticals Limited

Annual General Meeting

Monday, 04 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Non-Binding Resolution to adopt Remuneration Report	P	504,475,568	466,114,338 92.40%	34,371,026 6.81%	2,602,479	3,990,204 0.79%	474,143,580 93.24%	34,371,026 6.76%	2,602,479	Passed
2 Re-election of Dr William Bosch as a Director	P	612,084,770	581,645,803 95.03%	25,407,595 4.15%	183,060	5,031,372 0.82%	591,371,097 95.88%	25,407,595 4.12%	183,060	Passed
3 Ratification of issue of Placement Shares to institutional and sophisticated investors	P	215,582,131	199,729,120 92.65%	11,869,760 5.51%	115,073,530	3,983,251 1.85%	207,650,601 94.59%	11,869,760 5.41%	115,073,530	Passed
4 Increase in Directors' Fees	P	505,685,269	469,212,202 92.79%	32,564,242 6.44%	20,229,480	3,908,825 0.77%	477,120,065 93.60%	32,604,242 6.40%	20,229,480	Passed
5 Approval of Amended Plan	P	504,403,278	402,566,102 79.81%	97,774,474 19.38%	2,674,769	4,062,702 0.81%	410,667,842 80.77%	97,774,474 19.23%	2,674,769	Passed
6 Grant of Incentive Performance Rights to Mr Vince Ippolito or his nominee(s)	P	504,250,039	462,485,786 91.72%	37,842,887 7.50%	2,826,746	3,921,366 0.78%	470,446,190 92.55%	37,842,887 7.45%	2,826,746	Passed
7 Grant of Incentive Performance Rights to Mr Matthew Callahan or his nominee(s)	P	505,850,039	464,085,786 91.74%	37,842,887 7.48%	1,226,746	3,921,366 0.78%	472,046,190 92.58%	37,842,887 7.42%	1,226,746	Passed
8 Grant of Incentive Performance Rights to Dr Stewart Washer or his nominee(s)	P	505,852,039	324,211,660 64.09%	177,719,013 35.13%	1,224,746	3,921,366 0.78%	330,872,064 65.06%	177,719,013 34.94%	2,524,746	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Grant of Incentive Performance Rights to Dr William Bosch or his nominee(s)	P	505,852,039	338,838,762 66.98%	163,082,893 32.24%	20,061,448	3,930,384 0.78%	345,508,184 67.93%	163,082,893 32.07%	21,361,448	Passed
10 Grant of Incentive Performance Rights to Mr Danny Sharp or his nominee(s)	P	505,853,777	324,189,660 64.09%	177,719,013 35.13%	3,354,321	3,945,104 0.78%	330,873,802 65.06%	177,719,013 34.94%	4,654,321	Passed
11 Appointment of Auditor	P	612,164,746	606,385,297 99.06%	832,224 0.14%	103,084	4,947,225 0.81%	616,026,444 99.87%	832,224 0.13%	103,084	Passed
12 Renewal of proportional takeover provisions in Constitution	P	608,666,448	602,479,259 98.98%	2,294,230 0.38%	3,601,382	3,892,959 0.64%	611,066,140 99.63%	2,294,230 0.37%	3,601,382	Passed
13 Approval of potential termination benefits to Mr Vince Ippolito in relation to Incentive Performance Rights	P	503,711,877	471,661,326 93.64%	28,183,413 5.60%	3,366,170	3,867,138 0.77%	479,567,502 94.45%	28,183,413 5.55%	3,366,170	Passed
14 Approval of potential termination benefits to Mr Matthew Callahan in relation to Incentive Performance Rights	P	503,711,877	471,661,326 93.64%	28,183,413 5.60%	3,366,170	3,867,138 0.77%	479,567,502 94.45%	28,183,413 5.55%	3,366,170	Passed
15 Approval of potential termination benefits to Dr Stewart Washer in relation to Incentive Performance Rights	P	503,711,877	328,500,560 65.22%	171,344,179 34.02%	3,366,170	3,867,138 0.77%	335,106,736 66.17%	171,344,179 33.83%	4,666,170	Passed
16 Approval of potential termination benefits to Dr William Bosch in relation to Incentive Performance Rights	P	503,711,877	343,136,680 68.12%	156,708,059 31.11%	22,202,872	3,867,138 0.77%	349,742,856 69.06%	156,708,059 30.94%	23,502,872	Passed
17 Approval of potential termination benefits to Mr Danny Sharp in relation to Incentive Performance Rights	P	503,711,877	328,480,560 65.21%	171,364,179 34.02%	5,497,483	3,867,138 0.77%	335,086,736 66.16%	171,364,179 33.84%	6,797,483	Passed

